B · Normal
October 27th: GlaxoSmithKline expects to nearly double the number of cancer drugs in its clinical trials next year.
Related telegraphs
On October 27, AstraZeneca (AZN)’s ENHERTU was approved in the European Union fo
10-27 15:34
On October 27, the CEO of Novartis said that sales of ribrutinib are still likel
10-27 14:59
[Insilico Intelligent: Announced preliminary positive data from the first-in-hum
10-27 09:25
[Sino Biopharmaceuticals: TQ-A3334 and TQA3605 were included in the breakthrough
10-27 08:31
[Merck’s ADC drug reduces the risk of death in patients with advanced endometria
10-26 23:38
[Ascletis Pharmaceuticals: A new drug clinical trial application for ASC39 oral
10-26 08:21
Comments